GlassScriptPhysician profile
Yahaira A Sanchez
NPI 1336806710
$5,824.57
in general payments reported to CMS, 2019-2025
23 companies · $1,878 in 2025
The $1,878 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.65 · 2022: $1,640 · 2023: $1,037 · 2024: $1,252 · 2025: $1,878.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,166.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,348.07 | 2022-2025 | |
| Ardelyx, INC. | $1,136.82 | 2023-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $435.77 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $427.09 | 2022-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $297.57 | 2022-2025 | Entyvio |
| Redhill Biopharma INC. | $280.02 | 2022-2024 | Talicia |
| Phathom Pharmaceuticals, INC. | $194.15 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $120.49 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $96.56 | 2022 | |
| Ironwood Pharmaceuticals, INC | $61.75 | 2022-2023 | Linzess |
| Evoke Pharma, INC. | $59.89 | 2024 | |
| Echosens North America, INC. | $49.82 | 2025 | Fibroscan |
| Vivus LLC | $45.03 | 2024 | Qsymia |
| Intercept Pharmaceuticals, INC. | $44.78 | 2021-2024 | |
| Janssen Biotech, INC. | $43.80 | 2025 | Tremfya |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $37.60 | 2025 | Sucraid |
| Alnylam Pharmaceuticals INC. | $29.50 | 2024 | Oxlumo |
| Daiichi Sankyo INC. | $26.04 | 2024 | Injectafer |
| Merck Sharp & Dohme LLC | $22.32 | 2023 | Dificid |
| Exact Sciences Corporation | $18.62 | 2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $17.76 | 2025 | Wegovy |
| Enterra Medical, INC. | $15.97 | 2025 | |
| Pfizer INC. | $15.15 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yahaira Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.